MCID: OVR078
MIFTS: 56

Ovarian Cancer, Somatic malady

Genetic diseases (common), Cancer diseases categories

Aliases & Classifications for Ovarian Cancer, Somatic

About this section

Aliases & Descriptions for Ovarian Cancer, Somatic:

Name: Ovarian Cancer, Somatic 49 11
Adenocarcinoma, Ovarian, Somatic 49 11
Ovarian Carcinoma, Somatic 49 22
Epithelial Ovarian Cancer 65 67
Primary Malignant Neoplasm of Ovary 65
 
Malignant Neoplasm of Ovary 65
Ovarian Carcinoma 65
Ovarian Neoplasm 65
Ovarian Cancer 67
Oc 67


Classifications:



External Ids:

OMIM49 167000
ICD1027 C56
MeSH36 D010051

Summaries for Ovarian Cancer, Somatic

About this section
OMIM:49 Ovarian cancer, the leading cause of death from gynecologic malignancy, is characterized by advanced presentation with... (167000) more...

MalaCards based summary: Ovarian Cancer, Somatic, also known as adenocarcinoma, ovarian, somatic, is related to colonic disease and female reproductive system disease, and has symptoms including autosomal dominant inheritance, abnormality of metabolism/homeostasis and breast carcinoma. An important gene associated with Ovarian Cancer, Somatic is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Alpha), and among its related pathways are E-cadherin signaling in keratinocytes and FGF signaling pathway. The drugs chlorambucil and cisplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and lung, and related mouse phenotypes are no phenotypic analysis and adipose tissue.

UniProtKB/Swiss-Prot:67 Ovarian cancer: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

Related Diseases for Ovarian Cancer, Somatic

About this section

Diseases related to Ovarian Cancer, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 932)
idRelated DiseaseScoreTop Affiliating Genes
1colonic disease30.8AKT1, CTNNB1, PIK3CA
2female reproductive system disease30.8AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
3brca2 hereditary breast and ovarian cancer syndrome30.7BRCA1, BRCA2, PALB2
4male reproductive system disease30.5AKT1, BRCA1, BRCA2, CDH1
5nutritional deficiency disease30.5BRCA1, BRCA2
6stomach disease30.3CDH1, CTNNB1, ERBB2, KRAS, PIK3CA
7bronchial disease30.3CDH1, ERBB2
8renal cell carcinoma30.2AKT1, CDH1, KRAS, PIK3CA
9lung cancer susceptibility 330.2CDH1, ERBB2, KRAS
10gastrointestinal system disease30.0AKT1, CDH1, CTNNB1, ERBB2, KRAS, PIK3CA
11amyloid tumor30.0BRCA1, BRCA2, PIK3CA
12fallopian tube carcinosarcoma30.0BRCA1, BRCA2, ERBB2
13endometrial stromal tumor29.9CTNNB1, ERBB2, KRAS
14colon sarcoma29.8CDH1, CTNNB1, KRAS
15extrahepatic bile duct small cell adenocarcinoma29.8BRCA1, BRCA2, ERBB2
16bile duct adenocarcinoma29.7BRCA1, BRCA2, ERBB2
17lung cancer29.7AKT1, CDH1, CTNNB1, ERBB2, KRAS, NEU1
18gallbladder disease29.7CDH1, CTNNB1, ERBB2, KRAS
19thyroid gland disease29.7CDH1, CTNNB1, KRAS, PIK3CA
20prostate cancer29.5AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
21gastric cancer, somatic29.5CDH1, ERBB2, KRAS, NEU1, PIK3CA
22esophageal cancer29.5AKT1, CDH1, CTNNB1, ERBB2, KRAS, PIK3CA
23colorectal cancer29.4AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
24pancreatic islet cell tumors29.4BRCA1, BRCA2, KRAS, PALB2
25breast cancer29.2AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
26ovarian carcinosarcoma28.8AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
27ovarian disease11.3
28female reproductive organ cancer11.3
29endocrine gland cancer11.3
30gonadal disease11.3
31ovarian epithelial cancer11.1
32reproductive system disease11.1
33peritoneum cancer11.1
34fallopian tube cancer11.0
35fallopian tube disease11.0
36hereditary breast ovarian cancer10.9
37primary peritoneal carcinoma10.9
38gastrointestinal system cancer10.8
39peritonitis10.8
40endotheliitis10.8
41multiple endocrine neoplasia10.8
42oral cancer10.8
43oral cavity cancer10.8
44hematologic cancer10.7
45female breast carcinoma10.7
46adenocarcinoma10.7
47multiple endocrine neoplasia 110.7
48familiar ovarian carcinoma10.7
49cell type cancer10.7
50endometrial cancer10.7

Graphical network of the top 20 diseases related to Ovarian Cancer, Somatic:



Diseases related to ovarian cancer, somatic

Symptoms for Ovarian Cancer, Somatic

About this section

Symptoms by clinical synopsis from OMIM:

167000

Clinical features from OMIM:

167000

HPO human phenotypes related to Ovarian Cancer, Somatic:

id Description Frequency HPO Source Accession
1 autosomal dominant inheritance HP:0000006
2 abnormality of metabolism/homeostasis HP:0001939
3 breast carcinoma HP:0003002
4 ovarian papillary adenocarcinoma HP:0006774
5 dysgerminoma HP:0100621

Drugs & Therapeutics for Ovarian Cancer, Somatic

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Doxil15 41 DOXORUBICIN HYDROCHLORIDE Alza June 1999
FDA Label: Doxil
Disease/s that Drug Treats:ovarian cancer that is refractory to other first-line therapies
Indications and Usage:15 DOXIL is an anthracycline topoisomerase II inhibitor indicated for: Ovarian cancer (1.1)After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma (1.2)After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma (1.3)In combination with bortezomib in patients who have not previouslyreceived bortezomib and have received at least one prior therapy.
DrugBank Targets:13 1. DNA;2. DNA topoisomerase 2-alpha
Mechanism of Action:15 
Target: nucleic acidsynthesis
Action: inhibitor
FDA: The active ingredient of DOXIL is doxorubicin HCl. The mechanism of action ofdoxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acidsynthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclearReference ID: 373359617 chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, andinduction of mutagenesis and chromosomal aberrations.
2
Ethyol15 AMIFOSTINE Alza December 8, 1995
FDA Label: Ethyol
Disease/s that Drug Treats:ovarian cancer
Indications and Usage:15 ETHYOL (amifostine) is indicated to reduce the cumulative renal toxicity associated withrepeated administration of cisplatin in patients with advanced ovarian cancer.ETHYOL is indicated to reduce the incidence of moderate to severe xerostomia in patientsundergoing post-operative radiation treatment for head and neck cancer, where the radiationport includes a substantial portion of the parotid glands (see Clinical Studies).For the approved indications, the clinical data do not suggest that the effectiveness of cisplatin basedchemotherapy regimens or radiation therapy is altered by ETHYOL. There are at present only limiteddata on the effects of ETHYOL on the efficacy of chemotherapy or radiotherapy in other settings.ETHYOL should not be administered to patients in other settings where chemotherapy can produce asignificant survival benefit or cure, or in patients receiving definitive radiotherapy, except in thecontext of a clinical study (see WARNINGS).
DrugBank Targets:13 1. Ectonucleotide pyrophosphatase/phosphodiesterase family member 1;2. Alkaline phosphatase, placental-like
Mechanism of Action:15 
Target: -
Action: -
FDA: -
3
Hycamtin15 41 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/ May 1996
FDA Label: Hycamtin
Disease/s that Drug Treats:small cell lung cancer/ ovarian cancer
Indications and Usage:15 HYCAMTIN for injection is a topoisomerase inhibitor indicated for: metastatic carcinoma of the ovary after disease progression on or afterinitial or subsequent chemotherapy. (1.1) small cell lung cancer platinum-sensitive disease in patients whoprogressed after first-line chemotherapy. (1.2) combination therapy with cisplatin for Stage IV-B, recurrent, orpersistent carcinoma of the cervix which is not amenable to curativetreatment. (1.3)
DrugBank Targets:13 1. DNA topoisomerase 1;2. DNA topoisomerase I, mitochondrial;3. DNA
Mechanism of Action:15 
Target: topoisomerase I
Action: inhibitor
FDA: Topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand breaks.Topotecan binds to the topoisomerase I-DNA complex and prevents re-ligation of these singlestrandbreaks. The cytotoxicity of topotecan is thought to be due to double-strand DNA damageproduced during DNA synthesis, when replication enzymes interact with the ternary complexformed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repairthese double-strand breaks.
4
Lynparza15 41 OLAPARIB AstraZeneca December 2014
FDA Label: Lynparza
Disease/s that Drug Treats:previously treated BRCA mutated advanced ovarian cancer
Indications and Usage:15 Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated asmonotherapy in patients with deleterious or suspected deleterious germlineBRCA mutated (as detected by an FDA-approved test) advanced ovariancancer who have been treated with three or more prior lines of chemotherapy.(1.1)The indication is approved under accelerated approval based on objectiveresponse rate and duration of response. Continued approval for this indicationmay be contingent upon verification and description of clinical benefit inconfirmatory trials. (1 1, 14)
DrugBank Targets:13 1. Poly [ADP-ribose] polymerase 1;2. Poly [ADP-ribose] polymerase 2;3. Poly [ADP-ribose] polymerase 3
Mechanism of Action:15 
Target: poly (ADP-ribose) polymerase (PARP)
Action: inhibitor
FDA: Lynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3.PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNArepair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mousexenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increasedcytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor modelswith deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition ofPARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasisand cell death.

Drugs for Ovarian Cancer, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Kavanutraceutical1239000-38-85281052

Interventional clinical trials:

(show all 11)
idNameStatusNCT IDPhase
1To Assess Efficacy of Olaparib Maintenance Monotherapy at Preventing or Delaying the Return of the CancerRecruitingNCT02476968Phase 4
2Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes MutationsNot yet recruitingNCT02392676Phase 3
3A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)RecruitingNCT01482715Phase 1, Phase 2
4An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene AmplificationRecruitingNCT01953926Phase 2
5Phase II Study of BMN 673Active, not recruitingNCT02286687Phase 2
6Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.RecruitingNCT02323568
7Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and SpecificityRecruitingNCT02518256
8Clinical Significance of Germline BRCA MutationsRecruitingNCT00579488
9Prevalence of BRCA in Patients With Ovarian CancerActive, not recruitingNCT02222883
10Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary PresentationNot yet recruitingNCT02664389
11A Study of Long-Term Responders on OlaparibNot yet recruitingNCT02489058

Search NIH Clinical Center for Ovarian Cancer, Somatic

Inferred drug relations via UMLS65/NDF-RT43:

Genetic Tests for Ovarian Cancer, Somatic

About this section

Genetic tests related to Ovarian Cancer, Somatic:

id Genetic test Affiliating Genes
1 Ovarian Cancer, Somatic22 AKT1, ERBB2, PIK3CA

Anatomical Context for Ovarian Cancer, Somatic

About this section

MalaCards organs/tissues related to Ovarian Cancer, Somatic:

33
Ovary, Breast, Lung, Cervix, Testes

Animal Models for Ovarian Cancer, Somatic or affiliated genes

About this section

MGI Mouse Phenotypes related to Ovarian Cancer, Somatic:

38 (show all 23)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00030129.3CDH1, CTNNB1, NEU1, OPCML, PARK2, PIK3CA
2MP:00053758.8AKT1, BRCA1, PIK3CA, RRAS2, TGFBR2
3MP:00053718.5BRCA1, BRCA2, CTNNB1, ERBB2, KRAS, PALB2
4MP:00053818.1BRCA1, BRCA2, CDH1, CTNNB1, ERBB2, KRAS
5MP:00053907.9AKT1, BRCA1, BRCA2, CTNNB1, ERBB2, NEU1
6MP:00053887.9AKT1, BRCA1, CTNNB1, ERBB2, KRAS, NEU1
7MP:00028737.8AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
8MP:00053697.7AKT1, BRCA1, CTNNB1, ERBB2, KRAS, NEU1
9MP:00053977.2AKT1, BRCA1, BRCA2, CTNNB1, KRAS, NEU1
10MP:00053867.2AKT1, BRCA1, BRCA2, CTNNB1, ERBB2, KRAS
11MP:00053807.2AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
12MP:00107717.0AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
13MP:00036316.8AKT1, BRCA1, BRCA2, CTNNB1, ERBB2, KRAS
14MP:00053896.7AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
15MP:00053876.7AKT1, BRCA1, BRCA2, CDH1, CTNNB1, KRAS
16MP:00053766.7AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
17MP:00020066.6AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
18MP:00053846.6AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
19MP:00107686.5AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
20MP:00053856.5AKT1, BRCA1, CDH1, CTNNB1, ERBB2, KRAS
21MP:00053786.0AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
22MP:00053796.0AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2

Publications for Ovarian Cancer, Somatic

About this section

Variations for Ovarian Cancer, Somatic

About this section

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Cancer, Somatic:

67
id Symbol AA change Variation ID SNP ID
1BRCA1p.Cys61GlyVAR_007757rs28897672
2BRCA1p.Cys1697ArgVAR_020702
3BRCA1p.Arg1699TrpVAR_020703
4CTNNB1p.Ser37CysVAR_017625
5CTNNB1p.Thr41IleVAR_017630
6OPCMLp.Pro95ArgVAR_055421
7PIK3CAp.His1047ArgVAR_026192

Clinvar genetic disease variations for Ovarian Cancer, Somatic:

5 (show all 41)
id Gene Variation Type Significance SNP ID Assembly Location
1KRASNM_033360.3(KRAS): c.35G> A (p.Gly12Asp)single nucleotide variantPathogenic, drug responsers121913529GRCh37Chr 12, 25398284: 25398284
2KRASNM_033360.3(KRAS): c.34G> A (p.Gly12Ser)single nucleotide variantPathogenic, drug responsers121913530GRCh37Chr 12, 25398285: 25398285
3PALB2NM_024675.3(PALB2): c.1050_1053delAACA (p.Thr351Argfs)deletionPathogenicrs515726060GRCh38Chr 16, 23635493: 23635496
4PIK3CANM_006218.2(PIK3CA): c.3140A> G (p.His1047Arg)single nucleotide variantPathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
5PIK3CANM_006218.2(PIK3CA): c.1633G> A (p.Glu545Lys)single nucleotide variantPathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
6PIK3CANM_006218.2(PIK3CA): c.1634A> C (p.Glu545Ala)single nucleotide variantPathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
7ERBB2NM_001005862.2(ERBB2): c.2480A> G (p.Asn827Ser)single nucleotide variantPathogenicrs28933370GRCh37Chr 17, 37881378: 37881378
8AKT1NM_005163.2(AKT1): c.49G> A (p.Glu17Lys)single nucleotide variantPathogenicrs121434592GRCh37Chr 14, 105246551: 105246551
9NC_012920.1: m.14743A> Gsingle nucleotide variantLikely pathogenicrs527236161GRCh37Chr MT, 14743: 14743
10MT-CYBNC_012920.1: m.14753C> Tsingle nucleotide variantLikely pathogenicrs527236162GRCh38Chr MT, 14753: 14753
11MT-CYBNC_012920.1: m.14784T> Csingle nucleotide variantLikely pathogenicrs527236163GRCh37Chr MT, 14784: 14784
12MT-CYBNC_012920.1: m.15058C> Tsingle nucleotide variantLikely pathogenicrs527236171GRCh37Chr MT, 15058: 15058
13MT-CYBNC_012920.1: m.15098A> Gsingle nucleotide variantLikely pathogenicrs527236172GRCh37Chr MT, 15098: 15098
14MT-CYBNC_012920.1: m.15314G> Asingle nucleotide variantLikely pathogenicrs527236176GRCh37Chr MT, 15314: 15314
15MT-CYBNC_012920.1: m.15328A> Gsingle nucleotide variantLikely pathogenicrs527236178GRCh37Chr MT, 15328: 15328
16MT-CYBNC_012920.1: m.15334C> Tsingle nucleotide variantLikely pathogenicrs527236179GRCh37Chr MT, 15334: 15334
17MT-CYBNC_012920.1: m.15363A> Gsingle nucleotide variantLikely pathogenicrs527236182GRCh37Chr MT, 15363: 15363
18MT-CYBNC_012920.1: m.15453T> Csingle nucleotide variantLikely pathogenicrs527236184GRCh37Chr MT, 15453: 15453
19MT-CYBNC_012920.1: m.15459C> Tsingle nucleotide variantLikely pathogenicrs527236186GRCh37Chr MT, 15459: 15459
20MT-CYBNC_012920.1: m.15511T> Csingle nucleotide variantLikely pathogenicrs527236188GRCh37Chr MT, 15511: 15511
21MT-CYBNC_012920.1: m.15884G> Asingle nucleotide variantLikely pathogenicrs527236195GRCh37Chr MT, 15884: 15884
22MT-TTNC_012920.1: m.15890C> Asingle nucleotide variantLikely pathogenicrs527236196GRCh37Chr MT, 15890: 15890
23MT-TTNC_012920.1: m.15928G> Asingle nucleotide variantLikely pathogenicrs527236198GRCh37Chr MT, 15928: 15928
24MT-TTNC_012920.1: m.15932T> Gsingle nucleotide variantLikely pathogenicrs527236199GRCh37Chr MT, 15932: 15932
25MT-TTNC_012920.1: m.15943T> Csingle nucleotide variantLikely pathogenicrs527236200GRCh37Chr MT, 15943: 15943
26MT-CYBNC_012920.1: m.15061A> Gsingle nucleotide variantLikely pathogenicrs527236205GRCh37Chr MT, 15061: 15061
27MT-CYBNC_012920.1: m.15148G> Asingle nucleotide variantLikely pathogenicrs527236206GRCh37Chr MT, 15148: 15148
28MT-CYBNC_012920.1: m.15259C> Tsingle nucleotide variantLikely pathogenicrs527236207GRCh37Chr MT, 15259: 15259
29MT-CYBNC_012920.1: m.15431G> Asingle nucleotide variantLikely pathogenicrs527236208GRCh37Chr MT, 15431: 15431
30MT-CYBNC_012920.1: m.15452C> Asingle nucleotide variantLikely pathogenicrs527236209GRCh37Chr MT, 15452: 15452
31MT-CYBNC_012920.1: m.15607A> Gsingle nucleotide variantLikely pathogenicrs527236210GRCh37Chr MT, 15607: 15607
32MT-CYBNC_012920.1: m.15670T> Csingle nucleotide variantLikely pathogenicrs527236211GRCh37Chr MT, 15670: 15670
33PIK3CANM_006218.2(PIK3CA): c.1634A> C (p.Glu545Ala)single nucleotide variantPathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
34CTNNB1NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys)single nucleotide variantLikely pathogenic, Pathogenicrs121913403GRCh37Chr 3, 41266113: 41266113
35PIK3CANM_006218.2(PIK3CA): c.1624G> A (p.Glu542Lys)single nucleotide variantPathogenicrs121913273GRCh37Chr 3, 178936082: 178936082
36PIK3CANM_006218.2(PIK3CA): c.1258T> C (p.Cys420Arg)single nucleotide variantPathogenicrs121913272GRCh37Chr 3, 178927980: 178927980
37BRCA2NM_000059.3(BRCA2): c.5682C> G (p.Tyr1894Ter)single nucleotide variantPathogenicrs41293497GRCh37Chr 13, 32914174: 32914174
38PIK3CANM_006218.2(PIK3CA): c.1637A> G (p.Gln546Arg)single nucleotide variantPathogenicrs397517201GRCh37Chr 3, 178936095: 178936095
39PARK2PARK2, DELdeletionPathogenic
40OPCMLNM_001012393.1(OPCML): c.263C> G (p.Pro88Arg)single nucleotide variantPathogenicrs137852691GRCh37Chr 11, 132527098: 132527098
41RRAS2NM_001177314.1(RRAS2): c.110A> T (p.Gln37Leu)single nucleotide variantPathogenicrs113954997GRCh37Chr 11, 14316390: 14316390

Cosmic variations for Ovarian Cancer, Somatic:

7 (show all 28)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
153264EGFRovary,NS,carcinoma,adenocarcinoma3
253227EGFRovary,NS,carcinoma,adenocarcinoma3
353213EGFRovary,NS,carcinoma,adenocarcinoma3
428286EGFRovary,NS,carcinoma,adenocarcinoma3
553228EGFRovary,NS,carcinoma,adenocarcinoma3
653232EGFRovary,NS,carcinoma,adenocarcinoma3
722992EGFRovary,NS,carcinoma,adenocarcinoma3
853230EGFRovary,NS,carcinoma,adenocarcinoma3
928511EGFRovary,NS,carcinoma,adenocarcinoma3
106224EGFRovary,NS,carcinoma,adenocarcinoma3
1153224EGFRovary,NS,carcinoma,adenocarcinoma3
1253226EGFRovary,NS,carcinoma,adenocarcinoma3
1353265EGFRovary,NS,carcinoma,adenocarcinoma3
1412373EGFRovary,NS,carcinoma,adenocarcinoma3
1553266EGFRovary,NS,carcinoma,adenocarcinoma3
16775PIK3CAovary,NS,carcinoma,adenocarcinoma3
17760PIK3CAovary,NS,carcinoma,adenocarcinoma3
181668065INSRRovary,NS,carcinoma,adenocarcinoma3
191674106CSMD3ovary,NS,carcinoma,adenocarcinoma3
201669654ORC2ovary,NS,carcinoma,adenocarcinoma3
211669397LRP2ovary,NS,carcinoma,adenocarcinoma3
221677803ING1ovary,NS,carcinoma,adenocarcinoma3
23727028EP300ovary,NS,carcinoma,adenocarcinoma3
241680748NOTCH3ovary,NS,carcinoma,adenocarcinoma3
251681052RAB4Bovary,NS,carcinoma,adenocarcinoma3
2610662TP53ovary,NS,carcinoma,adenocarcinoma3
2730798CTNNB1ovary,NS,carcinoma,adenocarcinoma3
281682212LIMK2ovary,NS,carcinoma,adenocarcinoma3

Expression for genes affiliated with Ovarian Cancer, Somatic

About this section
Search GEO for disease gene expression data for Ovarian Cancer, Somatic.

Pathways for genes affiliated with Ovarian Cancer, Somatic

About this section

Pathways related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

(show top 50)    (show all 71)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.7AKT1, CDH1, PIK3CA
29.7AKT1, CDH1, PIK3CA
39.6CDH1, CTNNB1, PIK3CA
49.6CDH1, CTNNB1, PIK3CA
5
VEGF Pathway (Tocris)
Show member pathways
9.6CDH1, CTNNB1, PIK3CA
69.5AKT1, ERBB2, KRAS
79.5AKT1, CTNNB1, KRAS
89.5CDH1, ERBB2, KRAS
99.5AKT1, PIK3CA, TGFBR2
109.4CDH1, CTNNB1, KRAS
119.4AKT1, CDH1, ERBB2, PIK3CA
129.4AKT1, CDH1, CTNNB1, PIK3CA
139.3AKT1, CDH1, CTNNB1, ERBB2
149.3AKT1, ERBB2, KRAS, PIK3CA
15
Show member pathways
9.3AKT1, ERBB2, KRAS, PIK3CA
16
Show member pathways
9.3AKT1, ERBB2, KRAS, PIK3CA
179.3AKT1, BRCA1, CTNNB1
189.3AKT1, CTNNB1, KRAS, PIK3CA
199.3AKT1, CTNNB1, KRAS, PIK3CA
209.3ERBB2, KRAS, RRAS2
219.1CDH1, CTNNB1, ERBB2, TGFBR2
22
Show member pathways
9.1AKT1, KRAS, PIK3CA, RRAS2
23
Show member pathways
9.1AKT1, KRAS, PIK3CA, RRAS2
24
VEGF Pathway (Qiagen)
Show member pathways
9.1AKT1, KRAS, PIK3CA, RRAS2
25
Show member pathways
9.1AKT1, KRAS, PIK3CA, TGFBR2
26
Show member pathways
9.1AKT1, KRAS, PIK3CA, TGFBR2
279.0AKT1, CTNNB1, KRAS, RRAS2
289.0AKT1, CTNNB1, KRAS, RRAS2
29
Show member pathways
9.0AKT1, CTNNB1, KRAS, RRAS2
30
Show member pathways
8.9AKT1, CTNNB1, ERBB2, PIK3CA, TGFBR2
31
Show member pathways
8.7AKT1, CDH1, CTNNB1, ERBB2, KRAS, PIK3CA
328.7AKT1, CDH1, CTNNB1, KRAS, RRAS2
338.7AKT1, CDH1, CTNNB1, KRAS, TGFBR2
34
Show member pathways
8.7AKT1, BRCA1, CTNNB1, KRAS, PIK3CA
35
Show member pathways
8.5AKT1, ERBB2, KRAS, RRAS2, TGFBR2
368.5AKT1, CTNNB1, ERBB2, KRAS, PIK3CA, RRAS2
37
Show member pathways
8.5AKT1, CTNNB1, ERBB2, KRAS, PIK3CA, RRAS2
38
Show member pathways
8.5AKT1, CTNNB1, ERBB2, KRAS, PIK3CA, TGFBR2
39
Show member pathways
8.5AKT1, CTNNB1, ERBB2, KRAS, PIK3CA, TGFBR2
40
Show member pathways
8.4AKT1, CDH1, CTNNB1, KRAS, PIK3CA, RRAS2
41
Show member pathways
8.3AKT1, BRCA2, ERBB2, KRAS, PIK3CA, TGFBR2
428.2AKT1, CTNNB1, KRAS, PIK3CA, RRAS2, TGFBR2
43
Show member pathways
8.2AKT1, CDH1, CTNNB1, ERBB2, KRAS, PIK3CA
44
Show member pathways
8.2AKT1, CDH1, CTNNB1, ERBB2, KRAS, PIK3CA
45
Show member pathways
8.1AKT1, CDH1, CTNNB1, KRAS, RRAS2, TGFBR2
467.9AKT1, BRCA1, BRCA2, CTNNB1, ERBB2, KRAS
47
Show member pathways
7.9AKT1, CDH1, CTNNB1, ERBB2, KRAS, RRAS2
487.7AKT1, BRCA2, CDH1, CTNNB1, ERBB2, KRAS
49
Show member pathways
7.6AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
507.6AKT1, BRCA1, BRCA2, CDH1, CTNNB1, KRAS

GO Terms for genes affiliated with Ovarian Cancer, Somatic

About this section

Cellular components related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1flotillin complexGO:001660010.4CDH1, CTNNB1
2apical junction complexGO:004329610.4CDH1, CTNNB1
3catenin complexGO:001634210.4CDH1, CTNNB1
4protein complexGO:00432348.6AKT1, BRCA1, BRCA2, CTNNB1, PARK2
5plasma membraneGO:00058866.1AKT1, BRCA1, CDH1, CTNNB1, ERBB2, KRAS

Biological processes related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

(show all 26)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of release of cytochrome c from mitochondriaGO:009020110.5AKT1, PARK2
2regulation of myelinationGO:003164110.4AKT1, CTNNB1
3trachea morphogenesisGO:006043910.4CTNNB1, TGFBR2
4trachea formationGO:006044010.4CTNNB1, TGFBR2
5protein K6-linked ubiquitinationGO:008502010.3BRCA1, PARK2
6inner cell mass cell proliferationGO:000183310.2BRCA2, PALB2
7phosphatidylinositol-mediated signalingGO:004801510.2AKT1, ERBB2, PIK3CA
8cellular processGO:000998710.2CTNNB1, RRAS2
9negative regulation of neuron deathGO:190121510.1AKT1, CTNNB1, PARK2
10cellular response to growth factor stimulusGO:007136310.1AKT1, CTNNB1, ERBB2
11single organismal cell-cell adhesionGO:001633710.0CDH1, CTNNB1, OPCML
12DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:000697810.0BRCA1, BRCA2
13chordate embryonic developmentGO:004300910.0BRCA1, BRCA2
14cellular response to indole-3-methanolGO:00716819.8BRCA1, CDH1, CTNNB1
15positive regulation of histone H3-K4 methylationGO:00515719.7BRCA1, CTNNB1
16chromosome breakageGO:00310529.6BRCA1, BRCA2, PALB2
17insulin receptor signaling pathwayGO:00082869.6AKT1, ERBB2, KRAS, PIK3CA
18fibroblast growth factor receptor signaling pathwayGO:00085439.6AKT1, ERBB2, KRAS, PIK3CA
19Fc-epsilon receptor signaling pathwayGO:00380959.6AKT1, ERBB2, KRAS, PIK3CA
20double-strand break repair via synthesis-dependent strand annealingGO:00450039.5BRCA1, BRCA2, PALB2
21epidermal growth factor receptor signaling pathwayGO:00071739.4AKT1, ERBB2, KRAS, PIK3CA
22response to drugGO:00424939.3CDH1, CTNNB1, ERBB2, TGFBR2
23positive regulation of gene expressionGO:00106289.1BRCA1, CTNNB1, KRAS, PARK2
24vascular endothelial growth factor receptor signaling pathwayGO:00480109.0AKT1, ERBB2, KRAS, PIK3CA
25small GTPase mediated signal transductionGO:00072648.7CDH1, CTNNB1, ERBB2, KRAS, RRAS2
26apoptotic processGO:00069158.5AKT1, BRCA1, CDH1, CTNNB1, TGFBR2

Molecular functions related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1enzyme bindingGO:00198999.4AKT1, BRCA1, CTNNB1, PARK2
2protein bindingGO:00055154.5AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2

Sources for Ovarian Cancer, Somatic

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet